Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 289 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor... August 6, 2024 Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results... March 27, 2023 For Small Cell Lung Cancer, Immunotherapy Drug Finally Brings Improved Survival October 3, 2018 Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... January 18, 2022 Load more HOT NEWS What Cancer Caregivers Should Know About Hospice Care at Home: A... FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in... Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer...
